Originally published by our sister publication Infectious Disease Special Edition
By IDSE News Staf
The FDA approved lenacapavir (Yeztugo, Gilead Sciences), an injectable HIV-1 capsid inhibitor, to be used as pre-exposure prophylaxis (PrEP) to reduce the risk for sexually acquired HIV in adults and adolescents weighing at least 35 kg, making it the first and only twice-yearly option for Americans who need or want PrEP.
Data show that almost 100% of participants who received lenacapavir in the